A recent article published in the Journal of Managed Care and Specialty Pharmacy (JMCP) attempts to make the case for a higher value-based cost-effectiveness threshold for one-time gene replacement therapies.
The process of even paying for such high-cost therapies, the article states, could be a key challenge for the U.S. health care system.
“Historically, the United States and other countries have demonstrated a willingness to support higher prices for health gains in rare diseases,” the article states. “However, payers may be ill-prepared to address reimbursement based on single administrations associated with gene therapies.”
To read the full article on JMCP, click here.